Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

[Soluble receptors for tumor necrosis factor and lipid metabolism as potential prognostic factors in patients with prostate cancer].

Afanas'eva OI, Razova OA, Utkina EA, Afanas'eva MI, Dmitrieva OA, Zharinov GM, Tavakalian NS, Neklasova NIu, Nikitina NA, Pokrovskiĭ SN.

Vopr Onkol. 2013;59(1):72-7. Russian.

PMID:
23814829
2.

Prognostic value of serum markers for prostate cancer.

Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P.

Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. Review.

PMID:
16019759
3.

Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.

J Urol. 2005 Dec;174(6):2181-5.

PMID:
16280760
4.

Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.

Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, Larson SM, Morris MJ.

J Clin Oncol. 2012 Feb 10;30(5):519-24. doi: 10.1200/JCO.2011.36.5791. Epub 2012 Jan 9.

5.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

6.

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH.

J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83.

7.

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH.

J Natl Cancer Inst. 2004 Apr 7;96(7):509-15.

8.

High-intensity focused ultrasound therapy for clinically localized prostate cancer.

Lee HM, Hong JH, Choi HY.

Prostate Cancer Prostatic Dis. 2006;9(4):439-43. Epub 2006 Jul 18.

PMID:
16847468
9.

IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.

Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.

Eur Urol. 2006 Feb;49(2):286-92; discussion 292. Epub 2005 Dec 7.

PMID:
16386354
10.

[How to use PSA in 2009].

Ponholzer A, Stoiber F, Loidl W, Rauchenwald M, Schramek P, Madersbacher S.

Wien Med Wochenschr. 2009;159(21-22):515-20. doi: 10.1007/s10354-009-0718-0. Review. German.

PMID:
19997836
11.

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.

Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN; ASCENT Investigators.

Cancer. 2008 Jun;112(11):2377-83. doi: 10.1002/cncr.23461.

12.

Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.

Michael A, Stephan C, Kristiansen G, Burckhardt M, Loening SA, Schnorr D, Jung K.

Prostate. 2005 Jan 1;62(1):34-9.

PMID:
15389818
13.

Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer.

Kuller LH, Thomas A, Grandits G, Neaton JD; Multiple Risk Factor Intervention Trial Research Group.

Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):373-7.

14.

C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.

Eklund CM, Tammela TL, Schleutker J, Hurme M.

Br J Cancer. 2009 Jun 16;100(12):1846-51. doi: 10.1038/sj.bjc.6605081. Epub 2009 May 12.

15.

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D; Southwest Oncology Group Trial 9346 (INT-0162).

J Clin Oncol. 2006 Aug 20;24(24):3984-90.

16.

Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.

D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH.

J Urol. 2003 Apr;169(4):1320-4.

PMID:
12629352
17.

Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.

Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, Neidhardt-Berard EM, Coiffier B.

J Clin Oncol. 1997 Feb;15(2):499-508.

PMID:
9053471
18.

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).

Aus G, Becker C, Lilja H, Khatami A, Pihl CG, Hugosson J.

Scand J Urol Nephrol. 2003;37(6):466-70.

PMID:
14675918
19.

Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment.

Josefsson A, Wikström P, Granfors T, Egevad L, Karlberg L, Stattin P, Bergh A.

Eur Urol. 2005 Oct;48(4):577-83.

PMID:
15990221
20.

[Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Haese A, Graefen M, Palisaar J, Huland E, Huland H.

Urologe A. 2003 Sep;42(9):1172-87. Review. German.

PMID:
14504750
Items per page

Supplemental Content

Write to the Help Desk